Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
Tsugumi Matsumoto,1,2 Takanori Tsuchiya,3 Takahiro Hirano,4 Thomas Laurent,4 Kazuhisa Matsunaga,1 Jiro Takata1 1Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; 2Inflammation and Immunology Therapeutic Area Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 3Patient Impact Anal...
Saved in:
Main Authors: | Matsumoto T (Author), Tsuchiya T (Author), Hirano T (Author), Laurent T (Author), Matsunaga K (Author), Takata J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database
by: Kazumasa Kamei, et al.
Published: (2021) -
Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021) -
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019) -
Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
by: Yujeong Kim, et al.
Published: (2020) -
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
by: Iku Niinomi, et al.
Published: (2019)